Diagnostic value of measuring serum CA 15-3, TPA, and TPS in women with breast cancer

Postepy Higieny i Medycyny Doswiadczalnej

Volumn 60, Issue , 2006, Pages 295-299

  ͆liwowska, Izabela ^a   Kopczyński, Zygmunt ^a   Grodecka Gazdecka, Sylwia ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Breast cancer; CA 15 3; TPA; TPS; Tumor markers

Indexed keywords

CA 15-3 ANTIGEN; PEPTIDE; TISSUE POLYPEPTIDE ANTIGEN; TISSUE POLYPEPTIDE SPECIFIC ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BLOOD; BREAST TUMOR; CANCER STAGING; FEMALE; HUMAN; MIDDLE AGED; PATHOLOGY; REMISSION; ROC CURVE; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CA-15-3 ANTIGEN; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; PEPTIDES; REMISSION INDUCTION; ROC CURVE; SENSITIVITY AND SPECIFICITY; TISSUE POLYPEPTIDE ANTIGEN; TUMOR MARKERS, BIOLOGICAL;

EID: 33846060359     PISSN: 00325449     EISSN: 17322693     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Barak V., Goike H., Panaretakis K.W., Einarsson R.: Clinical utility of cytokeratins as tumor markers. Clin. Biochem., 2004; 37: 529-540
2. Bottini A., Berruti A., Tampellini M., Morrica B., Brunelli A., Gnocchi E., Brizzi M.P., Aguggini S., Fara E., Alquati P., Dogliotti L.: Influence of neoadjuvant chemotherapy on serum tumor markers CA 15-3, MCA, CEA, TPS and TPA in breast cancer patients with operable disease. Tumour Biol., 1997; 18: 301-310
3. Brandys A., Pawlicki M., Skolyszewski J.: Further studies on the efficacy of inductive chemiotherapy in patients with locally advanced stage of mammary cancer. Przegl. Lek., 1995; 52: 111-114
4. D'Alessandro R., Roselli M., Ferroni P., Mariotti S., Spila A., Aloe S., Carone M.D., Abbolito M.R., Carlini S., Perri P., Ricciotti A., Botti C., Conti F., Vici P., Chiappetta N.R., Cognetti F., Buonomo O., Guadagni F.: Serum tissue polypeptide specific antigen (TPS): A complementary tumor marker to CA 15-3 in the management of breast cancer. Breast Cancer Res. Treat., 2001; 68: 9-19
5. Duffy M.J., Duggan C., Keane R., Hill A.D., McDermott E., Crown J., O'Higgins N.: High preoperative CA 15-3 concentrations predict adverse outcome in node-negative and node-positive breast cancer: study of 600 patients with histologically confirmed breast cancer. Clin. Chem., 2004; 50: 559-563
6. Einarsson R., Barak V.: TPSTM: A cytokeratin serum tumor marker for effective therapy control of cancer patients with focus on breast cancer. J. Clinical Ligand Assay, 1999; 22: 348-351
7. Einarsson R., Lindman H., Bergh J.: Use of TPS and CA 15-3 assays for monitoring chemotherapy in metastatic breast cancer patients. Anticancer Res., 2000; 20: 5089-5093
8. Findeisen R., Albrecht S., Richter B., Deutschmann K., Zimmermann T., Distler W.: Chemiluminometric determination of tissue polypeptide antigen (TPA), cancer antigen 15-3 (CA 15-3), carcinoembryonic antigen (CEA) in comparison with vascular endothelial growth factor (VEGF) in follow-up of breast cancer. Luminescence, 2000; 15: 283-289
9. Gion M., Mione R., Leon A.E., Dittadi R.: Comparison of the diagnostic accuracy of CA27.29 and CA15.3 in primary breast cancer. Clin. Chem., 1999; 45: 630-637
10. Kopczyñski Z., Thielemann A.: The value of tissue polypeptide specific antigen TPS determination in serum of women with breast cancer comparison to mucin-like associated antigen MCA and CA 15-3 antigen. Eur. J. Gynaecol. Oncol., 1998; 19: 503-507
11. Kopczyñski Z., Thielemann A., Konik I., Szczypiñska I.: Diagnostic value of 15-3 antigen (CA 15-3) in serum of women with breast cancer-comparison to mucin-like associated antigen (MCA). Med. Sci. Monit., 1999; 5: 415-420
12. Kurebayashi J., Yamamoto Y., Tanaka K., Kohno N., Kurosumi M., Moriya T., Nishimura R., Ogawa Y., Taguchi T.; Tumor Marker Study Group of the Japanese Breast Cancer Society, Japan: Significance of serum carcinoembryonic antigen and CA 15-3 in monitoring advanced breast cancer patients treated with systemic therapy: A large-scale retrospective study. Breast Cancer, 2003; 10: 38-44
13. Luboiñski G.: Treatment of initially inoperable breast cancer. Pol. Przegl. Chir., 1991; 63: 193-196
14. Luboiñski G.: Diagnosis and treatment of breast cancer. Post. Nauk Med. 1993; 6: 257-259
15. Massacesi C., Rocchi M.B., Marcucci F., Pilone A., Galeazzi M., Bonsignori M.: Serum tumor markers may precede instrumental response to chemotherapy in patients with metastatic cancer. Int. J. Biol. Markers, 2003; 18: 295-300
16. National Cancer Registry, The Maria Sklodowska-Curie Memorial Cancer Center Department of Epidemiology and Cancer Prevention, Warsaw 2003, Poland. Available from: http://85.128.14.124/krn/english (29.05.2006)
17. Ozyilkan O., Baltali E., Kirazli S.: CA 15-3, ceruloplasmin and tissue polypeptide specific antigen as a tumour marker panel in breast cancer. East. Afr. Med. J., 2000; 77: 291-294
18. Pawlicki M.: Treatment of advanced breast cancer. Onkol. Pol., 2001; 4: 25-30
19. Pawlicki M., Reinfuss M., Skolyszewski J., Brandys A., Krzemieniecki K., Zuchowska B., Gliñski B., Mitus J., Stelmach A.: Multimodality treatment of noninflammatory stage IIIb breast cancer. Pol. Prz. Chir., 1997; 69: 483-488
20. Pronk L.C., Stoter G., van Putten W.L., de Wit R.: The correlation of CA 15-3 and TPS with tumor course in patient with metastatic breast cancer. J. Cancer. Res. Clin. Oncol., 1997; 123: 128-132
21. Schuurman J.J., Bong S.B., Einarsson R.: Determination of serum tumor markers TPS and CA 15-3 during monitoring of treatment in metastatic breast cancer patients. Anticancer Res., 1996; 16: 2169-2172
22. Seker D., Kaya O., Adabag A., Necipoglu G., Baran I.: Role of preoperative plasma CA 15-3 and carcinoembryonic antigen levels in determining histopathologic conventional prognostic factors for breast cancer. World J. Surg., 2003; 27: 519-521
23. Seregni E., Coli A., Mazzucca N.; Italian Group RIA-IRMA Test, Italian Association of Nuclear Medicine: Circulating tumour markers in breast cancer. Eur. J. Nucl. Med. Mol. Imaging., 2004; 31(Suppl.1): S15-S22
24. Soletormos G., Nielsen D., Schioler V., Mouridsen H., Dombernowsky P.: Monitoring different stages of breast cancer using tumour markers CA 15-3, CEA and TPA. Eur. J. Cancer., 2004; 40: 481-486
25. Sliwowska I., Kopczyñski Z., Grodecka-Gazdecka S.: Evaluation of CA 15-3, TPS and TPA utility in breast cancer diagnostics. Diagn. Lab., 2005; 41: 357-366
26. Van Dalen A.: Significance of cytokeratin markers TPA, TPA (cyk), TPS and CYFRA 21.1 in metastatic disease. Anticancer Res., 1996; 16: 2345-2349
27. Van Dalen A., Barak V., Cremaschi A., Gion M., Molina R., Namer M., Stieber P., Sturgeon C., Einarsson R.: The prognostic significance of increasing marker levels in metastatic breast cancer patients with clinically complete remission, partial remission or stable disease. Int. J. Biol. Markers., 1998; 13: 10-15
28. Vyzula R., Dusek L., Zaloudik J., Demlova R., Klimes D., Selvekerova S.: Breast cancer and neoadjuvant therapy: any predictive marker? Neoplasma, 2004; 51: 471-480